Skip to main content
Clinical Trials/NCT02314429
NCT02314429CompletedPhase 1

Phase I Trial Evaluating the Safety of a Lactate Releasing Vaginal Ring for the Prophylaxis of Bacterial Vaginosis

University Ghent1 site in 1 country6 target enrollmentStarted: September 1, 2014Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 1
Status
Completed
Enrollment
6
Locations
1
Primary Endpoint
Absence/presence of visible cervicovaginal inflammation/irritation by colposcopy

Study Overview

Brief Summary

In this first-in-human volunteer phase I clinical trial, a vaginal ring that slowly releases lactic acid (racemic mixture) into the vaginal environment, will be inserted in healthy volunteering women and left in place for 7 days. The primary objective of this phase I study is to assess the safety and the tolerability of this new intravaginal delivery system.

The eventual goal of this and related studies is to develop a vaginal ring that reduces recurrences in women suffering from bacterial vaginosis, which is the commonest form of vaginal infection.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Masking
None

Eligibility Criteria

Ages
18 Years to 45 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Good general physical and mental health
  • •Presence of normal (lactobacilli-dominated) vaginal microbiota
  • •Prepared to take oral contraception during the study

Exclusion Criteria

  • •Pregnancy
  • •Lactation
  • •Systemic disease
  • •Menopause
  • •Recent use of antibiotics (<1 week before entering the study)
  • •Recent use of intravaginal products or devices (<1 week before enrolment)
  • •Presence of vaginal infection

Arms & Interventions

Vaginal Ring

Experimental

A vaginal ring that slowly releases lactic acid (racemic mixture) into the vaginal environment, will be inserted in healthy volunteering women and left in place for 7 days.

Intervention: Vaginal ring releasing lactic acid (racemic mixture) (Device)

Outcomes

Primary Outcomes

Absence/presence of visible cervicovaginal inflammation/irritation by colposcopy

Time Frame: 7 days after insertion

Absence/presence of visible cervicovaginal inflammation/irritation by colposcopy

Time Frame: 1 hour after insertion

Absence/presence of visible cervicovaginal inflammation/irritation by colposcopy

Time Frame: 2 hours after insertion

Absence/presence of visible cervicovaginal inflammation/irritation by colposcopy

Time Frame: 4 hours after insertion

Absence/presence of visible cervicovaginal inflammation/irritation by colposcopy

Time Frame: 8 hours after insertion

Absence/presence of visible cervicovaginal inflammation/irritation by colposcopy

Time Frame: 24 hours after insertion

Secondary Outcomes

  • Assessment of vaginal pH(each 30 minutes for 4 hours after insertion, and then each 60 minutes for the next 4 hours)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials